Maximizing treatment options for recurrent glioblastoma using whole genome sequencing
Glioblastoma Targeted Treatment Option Maximization by Whole Genome Sequencing
This study is testing if using whole genome sequencing can help find better treatment options for patients with recurrent glioblastoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | UMC Utrecht Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (The Hague) |
| Trial ID | NCT05186064 on ClinicalTrials.gov |
What this trial studies
This project aims to improve treatment for patients with recurrent glioblastoma (GBM) by utilizing whole genome sequencing (WGS) to identify potential targeted therapies. In Dutch medical centers, recurrent GBM patients will be discussed in tumor boards to determine eligibility for the GLOW study, which will involve 160 patients undergoing re-resection. The study seeks to generate clinical evidence for the routine use of WGS diagnostics to adapt treatment guidelines for this patient group, who currently have limited options and poor prognosis. By integrating extensive molecular diagnostics into standard care, the goal is to provide timely access to novel therapies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histopathologically confirmed IDH wild type glioblastoma experiencing their first recurrence after standard treatment.
Not a fit: Patients currently enrolled in other antitumor clinical trials or with significant medical conditions that could affect compliance may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly extend survival and improve quality of life for patients with recurrent glioblastoma.
How similar studies have performed: While there have been challenges in previous trials for glioblastoma, the use of molecular diagnostics like WGS is a novel approach that has shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection; 2. Age ≥ 18 years; 3. Able and willing to give written informed consent; 4. Life expectancy \>3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity; 5. KPS performance status ≥70. Exclusion Criteria: 1. Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies); 2. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
Where this trial is running
The Hague
- Haaglanden Medisch Centrum — The Hague, Netherlands (Recruiting)
Study contacts
- Study coordinator: Mark Y van Opijnen
- Email: m.van.opijnen@haaglandenmc.nl
- Phone: 0031-88-9797900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.